Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.

摘要: PURPOSEIn a previously reported randomized Southeastern Cancer Study Group (SECSG) trial, three cycles of chemotherapy were found to be equivalent four in patients with favorable-prognosis germ-cell cancer. We have conducted follow-up analysis treated at Indiana University (Indianapolis, IN) compare long-term survival between the two groups and examine factors associated survival.PATIENTS AND METHODSSixty-nine minimal-stage 49 moderate-stage disseminated tumors either or courses bleomycin, etoposide, cisplatin (BEP) administered every 3 weeks. Median time is 10.1 years (range, 7 months 12.6 years). Ninety-two percent an actual > 5 years, 97.5% years.RESULTSSurvival shows no significant difference treatment terms overall (P = .80) disease-free .93) s...